CITY OF INDUSTRY, Calif.--(BUSINESS WIRE)--Prolacta Bioscience, Inc., the pioneer in human milk-based neonatal nutritional products, now offers the first and only ready-to-feed (RTF) human milk-derived premature infant formula, Prolact RTF™. It is made from 100% human donor milk, as opposed to cow milk, and is used when mother’s own milk is not available and fortification is needed. Prolact RTF provides optimal nutrition for premature infants in the neonatal intensive care unit (NICU).
The benefits of Prolact RTF include less risk of mixing errors and more efficient preparation time. It is a cost-effective way to provide a 100 percent human milk diet when mother’s own milk is not available.
“Prolact RTF now provides healthcare providers with an alternative to the traditional cow milk-based infant formula, when mother’s own milk is not available,” said Scott Elster, CEO of Prolacta Bioscience. “This product reduces the amount of time it takes to prepare feedings and significantly decreases the opportunity for mixing errors. It is a huge step forward for those babies without access to mom’s own milk.”
Clinical studies have shown that extremely premature infants (500 grams – 1250 grams at birth) who are fed a 100% human milk diet instead of preterm formula containing cow-milk protein have a significantly lower incidence of surgery associated with the intestinal disease necrotizing enterocolitis (NEC) and require fewer days of intravenous feedings through total parenteral nutrition (TPN).i One such clinical trial compared the duration of TPN, morbidities, and growth patterns in extremely premature infants fed exclusive diets of either cow milk-based preterm formula or donor human milk and human milk-based human milk fortifier (H2MF®). The trial was a clear comparison of the effects of formula versus donor human milk. The trial’s conclusion supported the use of a 100 percent human milk diet to nourish extremely preterm infants in the neonatal intensive care unit.
The American Academy of Pediatrics (AAP) recommends the use of human milk for all preterm infants, be it mother’s own milk or pasteurized donor human milk when mother’s own milk is unavailable. Premature infants are given superior protection when their nourishment begins with human milk, and the odds of developing NEC are reduced by 77% when infants are fed a 100 percent human-milk diet, as opposed to one containing cow milk.ii
Prolact RTF is part of a complete line of human milk-based Neonatal Nutritional Products that are clinically proven to improve health outcomes of critically ill preemies.
About Prolacta Bioscience
Prolacta Bioscience, Inc. is a privately-held life sciences company dedicated to Advancing the Science of Human Milk®. The company pioneered the development of human milk-based neonatal nutritional products to meet the needs of critically ill, premature infants in the NICU and leads the industry in the quality and safety of nutritional products made from donor breast milk. Prolacta operates the first and only pharmaceutical-grade manufacturing facility for the processing of human breast milk. For more information, please visit www.prolacta.com.
i Cristofalo E, et al. http://www.jpeds.com/article/S0022-3476(13)00865-2/
ii Sullivan S, et al. J Pediatr. 2010;156:562-567. doi:10.1014/j.jpeds.2009.10.040